​

Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)

ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$293.41

52W Range

$168.25 - $368.29

50D Avg

$286.92

200D Avg

$256.70

Market Cap

$6.73B

Avg Vol (3M)

$420.31K

Beta

-0.47

Div Yield

-

MDGL Company Profile

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

376

IPO Date

Feb 06, 2007

Website

MDGL Performance

MDGL Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-380.50M$-293.57M$-242.48M
Net Income$-373.63M$-299.31M$-241.08M
EBITDA$-380.50M$-291.39M$-242.48M
Basic EPS$-0.02$-17.47$-14.58
Diluted EPS$-0.02$-17.47$-14.58

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Oct 31, 24 | 2:50 PM
Q2 24Aug 07, 24 | 11:23 AM
Q1 24May 07, 24 | 12:00 AM

Peer Comparison

TickerCompany
TGTXTG Therapeutics, Inc.
PTCTPTC Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
STOKStoke Therapeutics, Inc.
PLRXPliant Therapeutics, Inc.
VKTXViking Therapeutics, Inc.
INZYInozyme Pharma, Inc.
XFORX4 Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
IOVAIovance Biotherapeutics, Inc.
SRPTSarepta Therapeutics, Inc.
KRYSKrystal Biotech, Inc.
ABOSAcumen Pharmaceuticals, Inc.
ETNB89bio, Inc.
TERNTerns Pharmaceuticals, Inc.
ACLXArcellx, Inc.
HEPAHepion Pharmaceuticals, Inc.